Literature DB >> 6885762

Leukotriene C4 binding to rat lung membranes.

S S Pong, R N DeHaven, F A Kuehl, R W Egan.   

Abstract

A high affinity binding site for leukotriene C4 (LTC4), one component of slow reacting substance of anaphylaxis, has been identified in a membrane preparation from rat lung. As measured by a filtration technique, [3H]LTC4 binding was saturable, specific, reversible, and heat-sensitive. In the presence of 20 mM CaCl2, the dissociation constant (KD) was 41 +/- 9 nM and the maximum number of binding sites (Bmax) was 31 +/- 10 pmol/mg of protein. Specificity was demonstrated by competition studies in which LTC4 had a Ki of 40 nM against specifically bound [3H]LTC4, whereas leukotriene D4 (LTD4) had a Ki of 4 microM. The stereoisomers (5R, 6R) LTC4, (5S, 6S) LTC4, and (5R, 6S) LTC4 had Ki values 3-, 15-, and 25-fold higher than that of natural (5S, 6R) LTC4. Leukotrienes E4 and B4, several prostaglandins and fatty acids, glutathione, and platelet activating factor were even less effective with Ki values above 10 microM. A slow reacting substance of anaphylaxis antagonist, FPL 55712, which, in some systems, distinguishes LTC4- from LTD4-induced contractions, was a weak competitor with a Ki of 16 microM. Serine-borate complex which inhibits gamma-glutamyl transpeptidase, an enzyme responsible for LTC4 metabolism, did not alter binding. In addition, 100 microM FPL 55712 did not reduce metabolism. These observations suggest that the binding observed for LTC4 may represent association with a physiological receptor for this molecule which has a relatively low affinity for LTD4.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6885762

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  11 in total

1.  Specificity and cellular distribution of human polymorphonuclear leucocyte receptors for leukotriene C4.

Authors:  L Baud; C H Koo; E J Goetzl
Journal:  Immunology       Date:  1987-09       Impact factor: 7.397

2.  Islet-activating protein inhibits leukotriene D4- and leukotriene C4- but not bradykinin- or calcium ionophore-induced prostacyclin synthesis in bovine endothelial cells.

Authors:  M A Clark; T M Conway; C F Bennett; S T Crooke; J M Stadel
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

3.  Renal vascular effects of leukotriene C4 in the isolated perfused kidney of the rat.

Authors:  J C Frölich; M Yoshizawa
Journal:  Br J Pharmacol       Date:  1987-10       Impact factor: 8.739

Review 4.  New developments concerning leukotriene antagonists: a review.

Authors:  J H Musser; A F Kreft; A J Lewis
Journal:  Agents Actions       Date:  1986-06

5.  Disruption of gamma-glutamyl leukotrienase results in disruption of leukotriene D(4) synthesis in vivo and attenuation of the acute inflammatory response.

Authors:  Z Z Shi; B Han; G M Habib; M M Matzuk; M W Lieberman
Journal:  Mol Cell Biol       Date:  2001-08       Impact factor: 4.272

Review 6.  The biologically active leukotrienes. Biosynthesis, metabolism, receptors, functions, and pharmacology.

Authors:  R A Lewis; K F Austen
Journal:  J Clin Invest       Date:  1984-04       Impact factor: 14.808

7.  Characterization of a leukotriene D4 receptor in guinea pig lung.

Authors:  S S Pong; R N DeHaven
Journal:  Proc Natl Acad Sci U S A       Date:  1983-12       Impact factor: 11.205

8.  Leukotriene E4-induced airway hyperresponsiveness of guinea pig tracheal smooth muscle to histamine and evidence for three separate sulfidopeptide leukotriene receptors.

Authors:  T H Lee; K F Austen; E J Corey; J M Drazen
Journal:  Proc Natl Acad Sci U S A       Date:  1984-08       Impact factor: 11.205

9.  Specific binding of leukotriene C4 to ileal segments and subcellular fractions of ileal smooth muscle cells.

Authors:  S Krilis; R A Lewis; E J Corey; K F Austen
Journal:  Proc Natl Acad Sci U S A       Date:  1984-07       Impact factor: 11.205

10.  Role of leukotrienes in airway hyperresponsiveness in guinea-pigs.

Authors:  K Ishida; R J Thomson; R R Schellenberg
Journal:  Br J Pharmacol       Date:  1993-03       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.